Jürgen Patzke
Research Subjects
Jürgen Patzke has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- François Depasse
Diagnostica Stago
3 shared publications Michael Spannagl
LMU University Hospital
3 shared publications- Nikolaus B. Binder
Deutsches Institut für Normung e.V. (DIN)
3 shared publications - Peter L. Turecek
University of Vienna
3 shared publications - Stephan Schwers
Deutsches Institut für Normung e.V. (DIN)
3 shared publications Mariona Bono
Deutsches Institut für Normung e.V. (DIN)
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (22) , 3845
Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study
Background: Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity. Methods: This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis. Results: Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity. Conclusions: Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.
- 18 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (22) , 3845
Open AccessComparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study
Background: Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity. Methods: This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis. Results: Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity. Conclusions: Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.
- Open Access
- 20 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (9) , 1037-1057
Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach
ADAMTS13, a crucial enzyme in hemostasis, that specifically cleaves von Willebrand factor (VWF), plays a pivotal role in the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura (TTP), a microcirculatory form of thrombotic microangiopathy (TMA). Its deficiency leads to the accumulation of ultra-large VWF multimers, causing microvascular thrombosis. Understanding and measuring ADAMTS13 activity are essential for diagnosis and management of TTP and other thrombotic diseases associated with ADAMTS13 deficiency. This review explores the evolution of ADAMTS13 assays from labor-intensive methods to rapid, automated platforms. It examines congenital and acquired ADAMTS13 deficiencies, highlighting diagnostic strategies and therapeutic interventions. A comprehensive literature search was conducted between September 2025 and June 2026 using PubMed and GoogleScholar, focusing on recent advancements and extending to foundational studies when necessary. The integration of rapid ADAMTS13 testing has the potential to improve clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. Despite progress, challenges remain in assay standardization, sensitivity, and interpretation. Future developments may include point-of-care technologies and conformation-sensitive assays to enhance relapse prediction and monitoring. Collaboration between clinicians and laboratories is crucial to optimize patient outcomes and advance the field of ADAMTS13 diagnostics.
- 20 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (9) , 1037-1057
Open AccessClinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach
ADAMTS13, a crucial enzyme in hemostasis, that specifically cleaves von Willebrand factor (VWF), plays a pivotal role in the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura (TTP), a microcirculatory form of thrombotic microangiopathy (TMA). Its deficiency leads to the accumulation of ultra-large VWF multimers, causing microvascular thrombosis. Understanding and measuring ADAMTS13 activity are essential for diagnosis and management of TTP and other thrombotic diseases associated with ADAMTS13 deficiency. This review explores the evolution of ADAMTS13 assays from labor-intensive methods to rapid, automated platforms. It examines congenital and acquired ADAMTS13 deficiencies, highlighting diagnostic strategies and therapeutic interventions. A comprehensive literature search was conducted between September 2025 and June 2026 using PubMed and GoogleScholar, focusing on recent advancements and extending to foundational studies when necessary. The integration of rapid ADAMTS13 testing has the potential to improve clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. Despite progress, challenges remain in assay standardization, sensitivity, and interpretation. Future developments may include point-of-care technologies and conformation-sensitive assays to enhance relapse prediction and monitoring. Collaboration between clinicians and laboratories is crucial to optimize patient outcomes and advance the field of ADAMTS13 diagnostics.
- Open Access
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (9) , 701-718
Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches
Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (9) , 701-718
Open AccessVon Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches
Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.
- Open Access
- 4 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (8) , 1-15
Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases
Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.
- 4 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (8) , 1-15
Open AccessReview of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases
Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.